nach oben

Virchows Archiv

Erschienen in:

23.07.2018 | Original Article

Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile

verfasst von: Satoshi Takahashi, Aye Aye Thike, Valerie Cui Yun Koh, Hironobu Sasano, Puay Hoon Tan

Erschienen in: Virchows Archiv | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

We compared the characteristics, clinical behavior, and biomarker profile between HER2 positive (HER2+) and triple-negative (TN) ductal carcinoma in situ (DCIS) which are considered more aggressive than other DCIS subtypes. In addition, we explored the impact of these features on its potential of progression to invasive breast carcinomas. Cases of DCIS diagnosed at the Department of Pathology, Singapore General Hospital from 1994 to 2010 were identified. TN and HER2+ DCIS cases formed the study cohort. Immunohistochemistry (IHC) was performed for ER, PR, HER2, CK14, EGFR, and p53. Comparisons of clinicopathological features, IHC results, and clinical outcomes were performed between the two groups. We evaluated 145 HER2+ and 85 TN DCIS cases. HER2 positive DCIS had significantly higher nuclear grade (p < 0.001) and more frequent necrosis (p < 0.001) than TN DCIS. HER2 positive DCIS also harbored significantly higher rates of nuclear p53 immunoreactivity (p = 0.002) than TN DCIS. Younger patients (age < 40) with HER2+ and TN DCIS demonstrated statistically significant worse invasive DFS than older women (p < 0.001). Multivariate cox regression analysis (HR 15.08, 95% CI 12.79–81.45, p = 0.002) also confirmed these findings. In addition, younger patients (age < 40) with HER2+ DCIS experienced significantly poorer prognosis when p53 was also positive (p = 0.033). HER2+ DCIS had more aggressive pathological characteristics compared to TN DCIS; accumulation of mutant p53 could possibly be contributory. Age was an independent predictor of aggressive biological behavior of HER2+ and TN DCIS. We demonstrated that younger patients with p53 positive HER2+ DCIS had significantly adverse clinical outcome.

Tan PH (2001) Pathology of ductal carcinoma in situ of the breast: a heterogeneous entity in need of greater understanding. Ann Acad Med Singap 30:671–676 quiz 677PubMed

Sanders ME, Schuyler PA, Dupont WD, Page DL (2005) The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103:2481–2484. https://doi.org/10.1002/cncr.21069 CrossRefPubMed

Boughey JC, Gonzalez RJ, Bonner E, Kuerer HM (2007) Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 12:1276–1287. https://doi.org/10.1634/theoncologist.12-11-1276 CrossRefPubMed

Cowell CF, Weigelt B, Sakr RA, Ng CKY, Hicks J, King TA, Reis-Filho JS (2013) Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol 7:859–869. https://doi.org/10.1016/j.molonc.2013.07.005 CrossRefPubMedPubMedCentral

Williams KE, Barnes NLP, Cramer A, Johnson R, Cheema K, Morris J, Howe M, Bundred NJ (2015) Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol 26:1019–1025. https://doi.org/10.1093/annonc/mdv062 CrossRefPubMed

Buerger H, Otterbach F, Simon R, Schäfer KL, Poremba C, Diallo R, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W (1999) Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 189:521–526. https://doi.org/10.1002/(SICI)1096-9896(199912)189:4<521::AID-PATH472>3.0.CO;2-B CrossRefPubMed

Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W (1999) Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 187:396–402. https://doi.org/10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L CrossRefPubMed

Zhou W, Jirström K, Amini R-M, Fjällskog ML, Sollie T, Lindman H, Sørlie T, Blomqvist C, Wärnberg F (2013) Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer 13:512. https://doi.org/10.1186/1471-2407-13-512 CrossRefPubMedPubMedCentral

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MCU, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502. https://doi.org/10.1001/jama.295.21.2492 CrossRefPubMed

10.

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MWR, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279. https://doi.org/10.1371/journal.pmed.1000279 CrossRefPubMedPubMedCentral

11.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members (2011) Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747. https://doi.org/10.1093/annonc/mdr304 CrossRefPubMedPubMedCentral

12.

Liao N, Zhang G, Liu Y, Li XR, Yao M, Xu FP, Li L, Wu YL (2011) HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. Pathol Res Pract 207:1–7. https://doi.org/10.1016/j.prp.2010.08.005 CrossRefPubMed

13.

Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G (2015) Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Ann Oncol 26:682–687. https://doi.org/10.1093/annonc/mdv013 CrossRefPubMed

14.

Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol JP, Lickley L, Paszat L, Hanna W (2008) Biological markers predictive of invasive recurrence in DCIS. Clin Med Oncol 2:7–18PubMedPubMedCentral

15.

Di Cesare P, Pavesi L, Villani L et al (2017) The relationships between HER2 overexpression and DCIS characteristics. Breast J 23:307–314. https://doi.org/10.1111/tbj.12735 CrossRefPubMed

16.

Mustafa RE, DeStefano LM, Bahng J et al (2017) Evaluating the risk of upstaging HER2-positive DCIS to invasive breast cancer. Ann Surg Oncol 24:2999–3003. https://doi.org/10.1245/s10434-017-5941-0 CrossRefPubMed

17.

Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750. https://doi.org/10.1093/jnci/djp082 CrossRefPubMedPubMedCentral

18.

Muñoz M, Fernández-Aceñero MJ, Martín S, Schneider J (2009) Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet 280:43–48. https://doi.org/10.1007/s00404-008-0867-1 CrossRefPubMed

19.

Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, Zappa M (2011) Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res 17:753–758. https://doi.org/10.1007/s12253-011-9381-z CrossRefPubMed

20.

Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374. https://doi.org/10.1158/1078-0432.CCR-04-0220 CrossRefPubMed

21.

Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, Easton D, Lakhani SR (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9:R4. https://doi.org/10.1186/bcr1636 CrossRefPubMedPubMedCentral

22.

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685. https://doi.org/10.1158/1078-0432.CCR-04-2421 CrossRefPubMed

23.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334. https://doi.org/10.1158/1078-0432.CCR-06-1109 CrossRefPubMed

24.

Zhou W, Jirström K, Johansson C, Amini RM, Blomqvist C, Agbaje O, Wärnberg F (2010) Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer 10:653. https://doi.org/10.1186/1471-2407-10-653 CrossRefPubMedPubMedCentral

25.

Bryan BB, Schnitt SJ, Collins LC (2006) Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19:617–621. https://doi.org/10.1038/modpathol.3800570 CrossRefPubMed

26.

Sarode VR, Han JS, Morris DH, Peng Y, Rao R (2011) A comparative analysis of biomarker expression and molecular subtypes of pure ductal carcinoma in situ and invasive breast carcinoma by image analysis: relationship of the subtypes with histologic grade, Ki67, p53 overexpression, and DNA ploidy. Int J Breast Cancer 2011:217060–217067. https://doi.org/10.4061/2011/217060 CrossRefPubMedPubMedCentral

27.

Ishikawa Y, Horiguchi J, Toya H, Nakajima H, Hayashi M, Tagaya N, Takeyoshi I, Oyama T (2011) Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features. Cancer Sci 102:656–662. https://doi.org/10.1111/j.1349-7006.2011.01858.x CrossRefPubMed

28.

Kurbel S (2013) In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer. Tumour Biol 34:1–7. https://doi.org/10.1007/s13277-012-0602-1 CrossRefPubMed

29.

Thike AA, Iqbal J, Cheok PY et al (2013) Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship. J Clin Pathol 66:665–670. https://doi.org/10.1136/jclinpath-2012-201428 CrossRefPubMed

30.

Koh VCY, Lim JCT, Thike AA et al (2015) Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat 152:293–304. https://doi.org/10.1007/s10549-015-3472-6 CrossRefPubMed

31.

Lakhani SR, Ellis IO, Schnitt SJ, et al (2012) WHO classification of tumours of the breast, 4th ed. IARC, Lyon

32.

Thike AA, Cheok PY, Jara-Lazaro AR et al (2010) Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23:123–133. https://doi.org/10.1038/modpathol.2009.145 CrossRefPubMed

33.

Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed

34.

Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/JCO.2013.50.9984 CrossRefPubMed

35.

Thike AA, Iqbal J, Cheok PY et al (2010) Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 34:956–964. https://doi.org/10.1097/PAS.0b013e3181e02f45 CrossRefPubMed

36.

Van Bockstal M, Lambein K, Denys H et al (2014) Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. Virchows Arch 465:275–289. https://doi.org/10.1007/s00428-014-1609-3 CrossRefPubMed

37.

Evans AJ, Pinder SE, Ellis IO, Wilson AR (2001) Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 8:149–151. https://doi.org/10.1136/jms.8.3.149 CrossRefPubMed

38.

Roka S, Rudas M, Taucher S et al (2004) High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol 30:243–247. https://doi.org/10.1016/j.ejso.2003.11.004 CrossRefPubMed

39.

Shamliyan T, Wang S-Y, Virnig BA et al (2010) Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010:121–129. https://doi.org/10.1093/jncimonographs/lgq034 CrossRefPubMedPubMedCentral

40.

Bijker N, Peterse JL, Duchateau L et al (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19:2263–2271. https://doi.org/10.1200/JCO.2001.19.8.2263 CrossRefPubMed

41.

Kikuchi S, Osako T, Nishiyama Y et al (2014) P53 overexpression in ductal carcinoma in situ of the breast. J Cytol Histol 5. https://doi.org/10.4172/2157-7099.1000269

42.

Rajan PB, Scott DJ, Perry RH, Griffith CD (1997) p53 protein expression in ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Res Treat 42:283–290CrossRefPubMed

43.

Jasar D, Smichkoska S, Kubelka K et al (2015) Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters. Pril (Makedon Akad Na Nauk Umet Oddelenie Za Med Nauki) 36:69–79

44.

de Roos MA, de Bock GH, de Vries J et al (2007) p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res 140:109–114. https://doi.org/10.1016/j.jss.2006.10.045 CrossRefPubMed

45.

Muller PAJ, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15:2–8. https://doi.org/10.1038/ncb2641 CrossRefPubMed

46.

Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310. https://doi.org/10.1038/35042675 CrossRefPubMed

47.

Oren M (2003) Decision making by p53: life, death and cancer. Cell Death Differ 10:431–442. https://doi.org/10.1038/sj.cdd.4401183 CrossRefPubMed

48.

Vicini FA, Shaitelman S, Wilkinson JB et al (2013) Long-term impact of young age at diagnosis on treatment outcome and patterns of failure in patients with ductal carcinoma in situ treated with breast-conserving therapy. Breast J 19:365–373. https://doi.org/10.1111/tbj.12127 CrossRefPubMed

49.

Kong I, Narod SA, Taylor C et al (2014) Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. Curr Oncol 21:e96–e104. https://doi.org/10.3747/co.21.1604 CrossRefPubMedPubMedCentral

50.

Roses RE, Paulson EC, Sharma A et al (2009) HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomark Prev 18:1386–1389. https://doi.org/10.1158/1055-9965.EPI-08-1101 CrossRef

51.

Harada S, Mick R, Roses RE et al (2011) The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease. J Surg Oncol 104:458–465. https://doi.org/10.1002/jso.21973 CrossRefPubMedPubMedCentral

52.

Wolf-Yadlin A, Kumar N, Zhang Y et al (2006) Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol 2:54. https://doi.org/10.1038/msb4100094 CrossRefPubMedPubMedCentral

53.

Subbaramaiah K, Howe LR, Port ER et al (2006) HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 66:5504–5511. https://doi.org/10.1158/0008-5472.CAN-05-4076 CrossRefPubMed

Titel: Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile
verfasst von: Satoshi Takahashi
Aye Aye Thike
Valerie Cui Yun Koh
Hironobu Sasano
Puay Hoon Tan
Publikationsdatum: 23.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 3/2018
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2416-z

Springer Medizin

Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Tumour origin and R1 rates in pancreatic resections: towards consilience in pathology reporting

Book review—Rosai and Ackerman’s surgical pathology-2 volume set, 11th edition

Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma

Misses and near misses in diagnosing nodular fasciitis and morphologically related reactive myofibroblastic proliferations: experience of a referral center with emphasis on frequency of USP6 gene rearrangements

Response to ‘Aberrant expression of TdT in seminomatous germ cell neoplasia’

In this issue

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie